🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

CEL-SCI Corp (CVM)

NYSE Amex
Currency in USD
2.3400
-0.0200(-0.85%)
Closed
CVM Scorecard
Full Analysis
Significant return over the last week
Fair Value
Day's Range
2.31002.3700
52 wk Range
1.02003.2300
Key Statistics
Edit
Bid/Ask
7.79 / 8.22
Prev. Close
2.36
Open
2.36
Day's Range
2.31-2.37
52 wk Range
1.02-3.23
Volume
16.01K
Average Volume (3m)
42.91K
1-Year Change
-13.65%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CVM Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.7330
Upside
+1,106.3963%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

CEL-SCI Corp Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company’s product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Employees
44

Compare CVM to Peers and Sector

Metrics to compare
CVM
Peers
Sector
Relationship
P/E Ratio
0.0x−1.6x−0.7x
PEG Ratio
0.00−0.040.00
Price/Book
0.0x0.6x2.6x
Price / LTM Sales
0.0x7.6x3.2x
Upside (Analyst Target)
0.0%250.9%47.1%
Fair Value Upside
Unlock7.2%7.3%Unlock

Analysts' Recommendations

2 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.7333

(+230.48% Upside)

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.